Navigation Links
iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
Date:7/7/2009

n was a professor at Stanford University and the University of California, Berkeley and is currently an adjunct professor at UCSF in the Departments of Anatomy and Biochemistry. While on the faculty at Berkeley, he was an investigator with the Howard Hughes Medical Institute, Evan Rauch Professor of Neuroscience, co-founder of the Wills Neuroscience Institute, and head of the division of neurobiology. Dr. Goodman also is a member of the National Academy of Sciences and was chairman of the National Research Council's board on Life Sciences, which issued in 2002 the landmark national report "Stem Cells and the Future of Regenerative Medicine.
  • Dr. Lee Rubin is director of Translational Medicine at the Harvard Stem Cell Institute. His research has focused on identifying therapeutics for disorders such as SMA, ALS, Huntington's disease and multiple sclerosis using novel stem cell-based screens and assays.
  • Dr. Lennart Mucke is the director of the Gladstone Institute of Neurological Disease, and a professor of Neurology and Neuroscience at UCSF. His research focuses on processes that result in memory loss and other major neurological deficits, with an emphasis on Alzheimer's disease and related neurodegenerative disorders.
  • Dr. Benoit Bruneau is an associate investigator at the Gladstone Institute of Cardiovascular Disease and associate professor in the department of Pediatrics at UCSF, and is an expert in cardiac differentiation. Dr. Bruneau's research focuses on the transcriptional regulation of heart development.
  • Dr. Kevin Eggan, assistant professor in the Department of Stem Cell and Regenerative Biology at Harvard University, principal investigator at the Harvard Stem Cell Institute, and assistant investigator at the Stowers Medical Institute. Dr. Eggan is a world authority on somatic cell reprogramming by nuclear transfer, and the applications of iPS cells to model ne
    '/>"/>

  • SOURCE iZumi Bio, Inc.; Pierian, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. The Gladstone Institutes and iZumi Bio Announce Broad Partnership in Regenerative Medicine and Cardiovascular Disease
    2. iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits
    3. iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer
    4. iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development
    5. iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board
    6. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
    7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
    8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
    9. ev3 and FoxHollow Announce Date for Special Meeting of FoxHollow Stockholders to Vote on Proposed Merger
    10. IsoTis - Integra Merger
    11. New Brunswick Scientific Completes Merger Transaction with Eppendorf
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... ... ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately held ... the three years through 2014. Being named to the Inc. 5000 list designates a ... , “We are thrilled to make the Inc. 5000 list for 2015,” stated ...
    (Date:8/26/2015)... Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended June 30, ... Canadian dollars and presented under International Financial Reporting ... with respect to our Oral Amp B program, ... manufacturer," said Andrew Rae , President & ...
    (Date:8/26/2015)... 26, 2015 Intrexon Corporation (NYSE: XON ... closing of its previously announced public offering of common ... of their option to purchase an additional 731,707 shares ... $41.00 per share.  The exercise of the underwriters, option ... sold by Intrexon to 5,609,756 shares and increased the ...
    (Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical ... relationships with local sponsors in southern California. The Clinical Trial Management Expert CRO seeks ... and regulatory pathways., , Stem Cell Meeting on the ...
    Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
    ... Sequella, Inc., a clinical-stage biopharmaceutical company focused ... receipt of a Small Business Innovation Research (SBIR) ... Allergy and Infectious Diseases (NIAID), National Institutes of ... the company,s novel tuberculosis (TB) lead dipiperidine drug ...
    ... the unexpected happens, www.WhatWillYourPlanBe.com offers post college-aged women ... healthMONTVALE, N.J., Feb. 17 Many young women ... go according to plan, particularly when it comes ... the reality is that the unexpected often happens ...
    ... to EUR1.06bn, - Adjusted Earnings per Share Improves by 36.6% From ... EBITDA Margin Rises From 19.0 to 19.5%, - CEO Dr. Axel ... considers itself well equipped to meet the global challenges in, ... in, the core business.", , ...
    Cached Biology Technology:Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609 2Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609 3Helping Young Women Succeed in Today's Unpredictable World 2Helping Young Women Succeed in Today's Unpredictable World 3Helping Young Women Succeed in Today's Unpredictable World 4Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009 2Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009 3Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009 4
    (Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
    (Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
    (Date:8/4/2015)... Research and ... addition of the "Digital Forensics Market ... (Computer Forensics, Network Forensics, Mobile Device Forensics, ... and Region - Global Forecast to 2020" ... By Component (Hardware, Software, and Service), Sub-Segment ...
    Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
    ... animals don,t pick their mates by pure chance it,s ... decades of examining his work, experts agree that he pretty ... is, "What have we learned since then?" asks a Texas ... an evolutional biologist who has studied Darwin,s work for years, ...
    ... RICHLAND, Wash. -- DNA might be the blueprint for ... to understand how and which proteins work together have ... unobtrusive enough to use in live cells. Using the ... a well-studied complex of proteins known as RNA polymerase. ...
    ... T-cells react to foreign protein fragments and therefore are ... attack the body,s own material are in most cases ... however, undergo a kind of reeducation to become "regulatory ... group led by immunologist Professor Ludger Klein of LMU ...
    Cached Biology News:Why do we choose our mates? Ask Charles Darwin, prof says 2TRAPping proteins that work together inside living cells 2TRAPping proteins that work together inside living cells 3They are young and need the job: A second chance for dangerous T-cells 2They are young and need the job: A second chance for dangerous T-cells 3
    Sf21 Insect Cells (Frozen) in Max-XP Medium...
    Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
    ... Ciphergen's ProteinChip arrays have been developed ... biological samples. A variety of ProteinChip ... proteins according to their unique biochemical ... spots, allowing side-by-side sample comparison, and ...
    ... ProteinChip arrays have been developed for ... samples. A variety of ProteinChip chemical ... according to their unique biochemical properties. ... allowing side-by-side sample comparison, and the ...
    Biology Products: